| Alexion Pharmaceuticalsannounced 30 Apr 2021 |
Initiate Phase 1 study of ALXN1850 in adults with HPP |
No record found30 Jun 2021 |
| Alexion Pharmaceuticalsannounced 30 Apr 2021 |
Resume Phase 1 study of ALXN1720 |
No record found30 Jun 2021 |
| Alexion Pharmaceuticalsannounced 4 Feb 2021 |
Receive Phase 1 data for ALXN2050 |
Met30 Jun 2021 |
| Alexion Pharmaceuticalsannounced 4 Feb 2021 |
Report results of the Phase 3 study of ULTOMIRIS in gMG |
No record found31 Dec 2021 |
| Alexion Pharmaceuticalsannounced 12 Jan 2021 |
Begin Phase 1 studies for ALXN1820 and ALXN1850 |
No record found30 Jun 2021 |
| Alexion Pharmaceuticalsannounced 12 Jan 2021 |
Close the acquisition of Alexion by AstraZeneca |
No record found30 Sep 2021 |
| Alexion Pharmaceuticalsannounced 12 Jan 2021 |
Report top-line data for the Phase 3 trial of ULTOMIRIS in gMG |
No record found31 Dec 2021 |
| Alexion Pharmaceuticalsannounced 29 Oct 2020 |
Initiate a Phase 3 bridging study of ALXN2060 for patients with ATTR-CM in Japan |
Met31 Dec 2020 |
| Alexion Pharmaceuticalsannounced 29 Oct 2020 |
Initiate a proof-of-concept trial of ULTOMIRIS in patients with IgA nephropathy and lupus nephritis |
Met31 Dec 2020 |
| Alexion Pharmaceuticalsannounced 29 Oct 2020 |
File for approval of ULTOMIRIS SC formulation and device combination in the U.S. and EU |
No record found30 Sep 2021 |
| Alexion Pharmaceuticalsannounced 30 Jul 2020 |
Initiate a Phase 3 study of ALXN2040 as an add-on therapy |
Met31 Dec 2020 |
| Alexion Pharmaceuticalsannounced 30 Jul 2020 |
Restart the Phase 1 study of ALXN1720 |
Met31 Dec 2020 |
| Alexion Pharmaceuticalsannounced 30 Jul 2020 |
Initiate a Phase 3 study of SOLIRIS in GBS in Japan |
Met31 Dec 2021 |
| Alexion Pharmaceuticalsannounced 30 Jul 2020 |
Begin Phase 1 and Phase 2 studies of subcutaneous ALXN1830 |
No record found31 Dec 2021 |
| Alexion Pharmaceuticalsannounced 6 May 2020 |
Initiate a Phase 3 study of ALXN2040 in PNH patients with EVH |
Met31 Dec 2020 |
| Alexion Pharmaceuticalsannounced 6 May 2020 |
Initiate a proof-of-concept trial of ULTOMIRIS in renal diseases |
Met31 Dec 2020 |
| Alexion Pharmaceuticalsannounced 6 May 2020 |
Begin Phase 2 study of subcutaneous ALXN1830 in gMG |
No record found31 Dec 2021 |
| Alexion Pharmaceuticalsannounced 30 Jan 2020 |
Initiate limited dose-ranging studies of ULTOMIRIS in HSCT-TMA |
Not met30 Jun 2020 |
| Alexion Pharmaceuticalsannounced 30 Jan 2020 |
Initiate Phase 2 dose selection for CAEL-101 |
Met30 Jun 2020 |
| Alexion Pharmaceuticalsannounced 30 Jan 2020 |
Initiate Phase 3 trials of ULTOMIRIS in HSCT-TMA |
Met31 Dec 2020 |
| Alexion Pharmaceuticalsannounced 30 Jan 2020 |
Initiate Phase 3 portion of the CAEL-101 program |
Met31 Dec 2020 |
| Alexion Pharmaceuticalsannounced 30 Jan 2020 |
Report results of the Phase 3 study of ALXN1840 in Wilson disease |
No record found30 Jun 2021 |
| Alexion Pharmaceuticalsannounced 13 Jan 2020 |
Report Phase 3 core data for once-weekly subcutaneous ULTOMIRIS |
Met30 Jun 2020 |
| Alexion Pharmaceuticalsannounced 23 Oct 2019 |
Deliver results from the Phase 3 PMM study |
Met31 Mar 2020 |
| Alexion Pharmaceuticalsannounced 23 Oct 2019 |
Expand the AG10 program into Japan |
Met31 Dec 2020 |
| Alexion Pharmaceuticalsannounced 16 Oct 2019 |
Submit IND application for ACH-5228 |
No record found31 Dec 2019 |
| Alexion Pharmaceuticalsannounced 16 Oct 2019 |
Report top line results for MMPOWER Phase 3 trial |
No record found31 Mar 2020 |
| Alexion Pharmaceuticalsannounced 16 Oct 2019 |
Close the acquisition of Achillion Pharmaceuticals |
Met30 Jun 2020 |
| Alexion Pharmaceuticalsannounced 16 Oct 2019 |
Initiate Phase 2 PNH study for ACH-5228 |
No record found31 Dec 2020 |
| Alexion Pharmaceuticalsannounced 24 Jul 2019 |
Initiate a Phase 3 study in children and adolescents with NMOSD |
Not met31 Dec 2019 |
| Alexion Pharmaceuticalsannounced 24 Jul 2019 |
Initiate a proof-of-concept study for ULTOMIRIS in ALS |
Met31 Mar 2020 |
| Alexion Pharmaceuticalsannounced 24 Jul 2019 |
Initiate a Phase 2/3 study of ALXN1830 in WAIHA |
No record found31 Mar 2020 |
| Alexion Pharmaceuticalsannounced 24 Jul 2019 |
Complete enrollment for the Phase 3 study of ALXN1840 |
Met31 Mar 2020 |
| Alexion Pharmaceuticalsannounced 25 Apr 2019 |
Initiate a first-in-human study of ALXN1720 |
Met31 Dec 2019 |
| Alexion Pharmaceuticalsannounced 25 Apr 2019 |
Initiate two Phase 2/3 trials of ALXN1830 |
No record found31 Mar 2020 |
| Alexion Pharmaceuticalsannounced 25 Apr 2019 |
Begin a Phase 2/3 study of CAEL-101 |
Met31 Mar 2020 |
| Alexion Pharmaceuticalsannounced 4 Feb 2019 |
Initiate Phase 3 study of ULTOMIRIS in gMG |
Met31 Mar 2019 |
| Alexion Pharmaceuticalsannounced 4 Feb 2019 |
File regulatory submission for ULTOMIRIS in aHUS in the U.S |
Met30 Jun 2019 |
| Alexion Pharmaceuticalsannounced 4 Feb 2019 |
File regulatory submission for SOLIRIS in Japan |
No record found31 Dec 2019 |
| Alexion Pharmaceuticalsannounced 4 Feb 2019 |
Initiate pivotal trial for ALXN1830 in WAIHA |
Not met31 Dec 2019 |
| Alexion Pharmaceuticalsannounced 4 Feb 2019 |
Report data from Phase 3 study of subcutaneous ULTOMIRIS |
Late31 Mar 2020 |
| Alexion Pharmaceuticalsannounced 24 Oct 2018 |
Submit regulatory applications for eculizumab in NMOSD |
Met31 Mar 2019 |
| Alexion Pharmaceuticalsannounced 24 Oct 2018 |
Initiate two pivotal trials for SYNT001 |
Not met31 Dec 2019 |
| Alexion Pharmaceuticalsannounced 1 Oct 2018 |
Close the acquisition of Syntimmune |
No record found31 Dec 2018 |
| Alexion Pharmaceuticalsannounced 26 Jul 2018 |
Report data from PREVENT study of Soliris in NMOSD |
Met31 Dec 2018 |
| Alexion Pharmaceuticalsannounced 26 Jul 2018 |
Initiate Phase 1 study of ALXN1810 |
Met31 Dec 2018 |
| Alexion Pharmaceuticalsannounced 26 Jul 2018 |
Report data from Phase 3 trial of ALXN1210 in aHUS |
Met31 Mar 2019 |
| Alexion Pharmaceuticalsannounced 26 Jul 2018 |
Launch ALXN1210 for PNH |
Met31 Dec 2019 |
| Alexion Pharmaceuticalsannounced 26 Apr 2018 |
File for regulatory approval for ALXN1210 in the U.S. and EU |
Met30 Jun 2018 |
| Alexion Pharmaceuticalsannounced 26 Apr 2018 |
File for regulatory approval for ALXN1210 in Japan |
Met31 Dec 2018 |
| Alexion Pharmaceuticalsannounced 11 Apr 2018 |
Close the acquisition of Wilson Therapeutics |
Met30 Jun 2018 |
| Alexion Pharmaceuticalsannounced 26 Oct 2017 |
Report data from the Phase 3 trial of eculizumab in patients with NMOSD |
Late30 Jun 2018 |
| Alexion Pharmaceuticalsannounced 12 Sep 2017 |
Relocate headquarters to Boston, MA |
Met30 Jun 2018 |
| Alexion Pharmaceuticalsannounced 27 Apr 2017 |
Initiate a Phase 3 PNH Switch study of ALXN1210 |
Met30 Jun 2017 |